Trial Profile
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Healthy Women of Nonchildbearing Potential
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 May 2014
Price :
$35
*
At a glance
- Drugs PRA 027 (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions
- Sponsors Pfizer
- 16 May 2014 New trial record